D
92.36
-1.08 (-1.16%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Dianthus Therapeutics, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
0.3
| 分析师共识 | NA |
| 内部交易活动 | NA |
| 价格波动 | -1.0 |
| 技术平均移动指标 | 2.5 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.33 |
|
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 7.87% |
| 机构持股比例 | 119.90% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Fairmount Funds Management Llc | 30 Jun 2026 | 2,537,191 |
| Avidity Partners Management Lp | 30 Jun 2026 | 2,104,184 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合